218 related articles for article (PubMed ID: 27895336)
1. Access to medicines report cards.
Mullard A
Nat Rev Drug Discov; 2016 Nov; 15(12):811. PubMed ID: 27895336
[No Abstract] [Full Text] [Related]
2. Access to medicines and the rhetoric of responsibility.
Barry C; Raworth K
Ethics Int Aff; 2002; 16(2):57-70. PubMed ID: 15709279
[No Abstract] [Full Text] [Related]
3. Creating reliable pharmaceutical distribution networks and supply chains in African countries: Implications for access to medicines.
Tetteh E
Res Social Adm Pharm; 2009 Sep; 5(3):286-97. PubMed ID: 19733829
[No Abstract] [Full Text] [Related]
4. The Health Impact Fund: incentives for improving access to medicines.
Banerjee A; Hollis A; Pogge T
Lancet; 2010 Jan; 375(9709):166-9. PubMed ID: 20109894
[No Abstract] [Full Text] [Related]
5. Access to medicines is not the business of the pharma industry.
Brown PJ
J Int Assoc Physicians AIDS Care (Chic); 2002; 1(1):9-11; discussion 12-4. PubMed ID: 12942664
[No Abstract] [Full Text] [Related]
6. TRIPS, pharmaceutical patents, and access to essential medicines: a long way from Seattle to Doha.
't Hoen E
Chic J Int Law; 2002; 3(1):27-46. PubMed ID: 15709298
[No Abstract] [Full Text] [Related]
7. Questions raised about whether compulsory licenses get best prices.
Owens B
Nat Med; 2015 Apr; 21(4):300. PubMed ID: 25849264
[No Abstract] [Full Text] [Related]
8. Out-licensing: a practical approach for improvement of access to medicines in poor countries.
Friedman MA; den Besten H; Attaran A
Lancet; 2003 Jan; 361(9354):341-4. PubMed ID: 12559883
[No Abstract] [Full Text] [Related]
9. Global "hold-em".
Cassidy BS
Geriatr Nurs; 2006; 27(1):21-3. PubMed ID: 16483897
[No Abstract] [Full Text] [Related]
10. Supporting the production of pharmaceuticals in Africa.
Dong J; Mirza Z
Bull World Health Organ; 2016 Jan; 94(1):71-2. PubMed ID: 26769999
[No Abstract] [Full Text] [Related]
11. Privatized Pharmaceutical Innovation vs Access to Essential Medicines: A Global Framework for Equitable Sharing of Benefits.
Burci GL; Gostin LO
JAMA; 2017 Feb; 317(5):473-474. PubMed ID: 28170485
[No Abstract] [Full Text] [Related]
12. Drug studies in developing countries.
Olliaro PL; Vijayan R; Inbasegaran K; Lang CC; Looareesuwan S
Bull World Health Organ; 2001; 79(9):894-5. PubMed ID: 11584742
[No Abstract] [Full Text] [Related]
13. Patent immorality?
Bloche MG; Jungman ER
Am J Bioeth; 2002; 2(3):48-9. PubMed ID: 12230859
[No Abstract] [Full Text] [Related]
14. EU agrees deal on cheaper drugs for developing world.
Watson R
BMJ; 2003 Jun; 326(7401):1229. PubMed ID: 12791716
[No Abstract] [Full Text] [Related]
15. Tripping over patents: AIDS, access to treatment and the manufacturing of scarcity.
Berger JM
Conn J Int Law; 2002; 17(2):157-248. PubMed ID: 12688292
[No Abstract] [Full Text] [Related]
16. Intellectual property and pharmaceutical drugs: an ethical analysis.
De George RT
Bus Ethics Q; 2005 Oct; 15(4):549-75. PubMed ID: 16358442
[TBL] [Abstract][Full Text] [Related]
17. The missing ingredient in medicine patent pools.
Gold ER; Morin JF
Lancet; 2009 Oct; 374(9698):1329-30. PubMed ID: 19837251
[No Abstract] [Full Text] [Related]
18. [An alternative and innovative Research and Development model to ensure access to medicines - Neglected diseases, neglected populations, and biomedical innovation system].
Pécoul B
Med Sci (Paris); 2016 Dec; 32(12):1049-1050. PubMed ID: 28044961
[No Abstract] [Full Text] [Related]
19. More drugs, less protection.
Nature; 2002 Sep; 419(6904):233. PubMed ID: 12239521
[No Abstract] [Full Text] [Related]
20. Seeking truer measures of success: Moving toward more rigorous evaluations of industry-led access to medicines programs.
Ramirez CL; Gajeelee A; Desharnais B; Sherman J; Waters D
J Glob Health; 2021 May; 11():03062. PubMed ID: 34055323
[No Abstract] [Full Text] [Related]
[Next] [New Search]
